Online Pharmacy Training

  Alzheimer’s disease is a progressive neurodegenerative disorder that affects millions of people worldwide, posing significant challenges for patients, caregivers, and healthcare systems. Despite extensive research, effective treatments remain elusive. In this context, the FDA Fast Track designation represents a beacon of hope, accelerating the development and review of potential therapies for Alzheimer’s disease. This article delves into the significance, process, and implications of the FDA Fast Track designation for Alzheimer’s treatments. Understanding FDA Fast Track Designation The Fast Track designation is a regulatory process designed by the U.S. Food and Drug Administration (FDA) to expedite the review of drugs intended to treat serious conditions and address unmet medical needs. This designation aims to get promising new therapies to patients sooner, without compromising safety and efficacy standards. Criteria for Fast Track Designation To qualify for Fast Track designati...

SOVALDI  It is a nucleotide analog polymerase inhibitor, that use in patients with chronic hepatitis C, in combination with ribavirin or interferon plus ribavirin, and the cure rate in clinical trials reached 95%. Here is some facts about SOVALDI that pharmacist must know: Active constituent of SOVALDI is sofosbuvir 400 mg. SOVALDI is effective against the four genotypes of HIV infection, including patients with HCC that in waiting list for liver transplantation, and those carrying HIV-1/HCV co-infection. SOVALDI not recommended using alone for Chronic Hepatitis C patients. The dose of SOVALDI is 400 mg once daily, to be taken regardless of food. Genotype-1 HCV treated for 12 weeks with SOVALDI +Peginterferon alfa +ribavirin, and for 24 weeks if used without peginterferon alfa. Genotype-2 HCV treated for 12 weeks with SOVALDI +ribavirin. Genotype-3 HCV treated for 24 weeks with SOVALDI +ribavirin. Genotype-4 treated for 12 weeks with SOVALDI +Peginterferon a...

HARVONI   It is a combination of ledipasvir (90mg), a (HCV) NS5A inhibitor, and sofosbuvir (400mg), an HCV nucleotide analog NS5B polymerase inhibitor. HARVONI was approved by FDA on 10  October  2014, as first Hepatitis C drug combination, that used alone without need to ribavirin or peginterferon alfa, as in case of SOVALDI. Harvoni 15 facts: Used for treatment of chronic hepatitis C (CHC) genotype 1 infection in adults. HARVONI dose is one tablet to be taken once daily regardless of food. Treatment duration varies according to the case and presence of liver cirrhosis. In naive cirrhotic or not, and in experienced non cirrhotic, they treated for 12 weeks. In naive non-cirrhotic patient with PCR < 6million IU/ml, treatment may reduced to 8 weeks. In experienced cirrhotic patients the treatment extends for 24 weeks. Experienced patients who have failed to treat with other medications. HARVONI used alone without the need to peginterferon al...

Serious and Life-Threatening Cases for use Harvoni and Sovaldi with amiodarone Serious and Life-Threatening Cases of Symptomatic Bradycardia, as well as One Case of Fatal Cardiac Arrest, Reported with Coadministration of amiodarone with either Harvoni® (ledipasvir and sofosbuvir fixed-dose combination) or with Sovaldi® (sofosbuvir) in combination with another direct-acting antiviral. The specific changes to each label are summarized below. Harvoni label changes: WARNINGS AND PRECAUTIONS Serious Symptomatic Bradycardia When Coadministered with Amiodarone Postmarketing cases of symptomatic bradycardia, including fatal cardiac arrest and cases requiring pacemaker intervention, have been reported when amiodarone is coadministered with HARVONI. Bradycardia has generally occurred within hours to days, but cases have been observed up to 2 weeks after initiating HCV treatment. Patients also taking beta blockers, or those with underlying cardiac comorbidities and/or advanced liver ...

U.S. Food and Drug Administration (FDA) has approved the dermal filler, Bellafill- polymethylmethacrylate (PMMA) collagen filler - for the treatment of skin condition scars. Bellafill represents a big clinical advancement because the solely filler on the market approved for this disfiguring skin condition. skin condition is that the commonest skin condition within the U.S., poignant 40-50 million people1 and up to ninety fifth of individuals with skin condition could endure to suffer from scarring.  Bellafill was studied extensively before its office approval and established to be safe and effective for the correction of moderate to severe, atrophic, expansive facial skin condition scars on the cheek in patients over the age of twenty one years.

FDA approved Lynparza for treatment of Advanced Ovarian Cancer The U.S. Food and Drug Administration nowadays granted accelerated approval to Lynparza (olaparib), a brand new drug treatment for ladies with advanced ovarian cancer related to defective BRCA genes, as detected by associate degree FDA-approved take a look at. Ovarian cancer forms within the ovary, one in all a try of feminine reproductive glands wherever ova, or eggs, are formed. The National Cancer Institute estimates that 21,980 american girls are going to be diagnosed with and 14,270 can die from ovarian cancer in 2014. Lynparza is a poly ADP-ribose enzyme (PARP) substance that blocks enzymes concerned in repairing broken DNA. it's meant for ladies with heavily pretreated gonad cancer that's related to defective BRCA genes. “Today’s approval constitutes the primary of a brand new category of medication for treating gonad cancer,” same Richard Pazdur, MD, director of the workplace of haematology and medicin...

The US Food and Drug Administration ( FDA ) has approved Natesto (testosterone),  once  CompleoTRT™,  the primary  and  solely  androgen  nasal gel for replacement  medical aid  in adult males for conditions  related to  a deficiency or absence of endogenous  androgen . Natesto is self-administered via a nasal  applier  thereby minimizing  the chance  of secondary exposure to  androgen   of girls  or  youngsters .

The U.S. Food and Drug Administration is advising consumers to immediately stop using a product called Mass Destruction, marketed as a dietary supplement for muscle growth. The product is labeled to contain at least one synthetic anabolic steroid and has been linked to at least one reported serious illness.

The U.S. Food and Drug Administration today announced it is requiring the removal of certain restrictions on prescribing and use of the diabetes drug Avandia (rosiglitazone) to reflect new information regarding the cardiovascular risk of the medicine. Today’s actions are consistent with the recommendations of expert advisory committees. Results from the Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycemia in Diabetes (RECORD) clinical trial showed no elevated risk of heart attack or death in patients being treated with Avandia when compared to standard-of-care diabetes drugs. These data do not confirm the signal of increased risk of heart attacks that was found in a meta-analysis of clinical trials first reported in 2007. In addition to Avandia, rosiglitazone is available in combination with other diabetes medications, including metformin under the brand name Avandamet and glimepiride under the brand name Avandaryl.  http://www.fda.go...

Is your medicine cabinet filled with expired drugs or medications you no longer use? How should you dispose of them? Most drugs can be thrown in the household trash, but consumers should take certain precautions before tossing them out, according to the Food and Drug Administration (FDA). A few drugs should be flushed down the toilet. And a growing number of community-based "take-back" programs offer another safe disposal alternative.

ISSUE : FDA is advising health care professionals against using magnesium sulfate injection for more than 5-7 days to stop pre-term labor in pregnant women. Administration of magnesium sulfate injection to pregnant women longer than 5-7 days may lead to low calcium levels and bone problems in the developing baby or fetus, including thin bones (osteopenia), and fractures. The shortest duration of treatment that can result in harm to the baby is not known. See the Data Summary in the Drug Safety Communication for additional information.

[3-12-2013]     The U.S. Food and Drug Administration (FDA) is warning the public that azithromycin (Zithromax or Zmax) can cause abnormal changes in the electrical activity of the heart that may lead to a potentially fatal irregular heart rhythm.

FRIDAY, January 20, 2012 - The U.S. Food and Drug Administration today approved Zetonna (ciclesonide) nasal aerosol to treat the symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older.

The US Food and Drug Administration has approved Subsys (fentanyl) sublingual spray. Subsys is a sublingually-administered formulation of fentanyl which provides relief to patients who experience episodes of breakthrough cancer pain. Breakthrough cancer pain is characterized by sudden, often unpredictable, episodes of intense pain which can peak in severity at three to five minutes despite background pain medication. Subsys is approved in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

The U.S. Food and Drug Administration (FDA) has approved Anturol (oxybutynin) topical gel 3% for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency.

The U.S. Food and Drug Administration has approved Intermezzo (zolpidem tartrate sublingual tablets) for use as needed to treat insomnia characterized by middle-of-the-night waking followed by difficulty returning to sleep.

The U.S. Food and Drug Administration (FDA) has approved Eylea (aflibercept) Injection, known in the scientific literature as VEGF Trap-Eye, for the treatment of patients with neovascular (wet) Age-related Macular Degeneration (AMD) at a recommended dose of 2 milligrams (mg) every four weeks (monthly) for the first 12 weeks, followed by 2 mg every eight weeks (2 months).

Clinical Context Tadalafil is a phosphodiesterase-5 (PDE5) inhibitor that was approved by the US Food and Drug Administration (FDA) in 2003 to treat erectile dysfunction (ED). The FDA has now expanded the approved indications to include benign prostatic hyperplasia (BPH), either alone or in combination with ED.

The U.S. Food and Drug Administration (FDA) has approved Onfi (clobazam), an oral benzodiazepine antiepileptic drug, as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) in patients two years and older.

October 14, 2011 -- The U.S. Food and Drug Administration today approved Ferriprox (deferiprone) to treat patients with iron overload due to blood transfusions in patients with thalassemia, a genetic blood disorder that causes anemia, who had an inadequate response to prior chelation therapy.